Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

By sjmartinez • February 17, 2023

Khanna D, Maher TM, Volkmann ER, Allanore Y, Smith V, Assassi S, Kreuter M, Hoffmann-Vold AM, Kuwana M, Stock C, Alves M, Sambevski S, Denton CP. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. RMD Open. 2023 Feb;9(1):e002859. doi: 10.1136/rmdopen-2022-002859. PMID: 36796874; PMCID: PMC9936273.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Scleroderma, Systemic, Therapeutics

Forearm BMD predicts fracture independently of FRAX

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Cauley JA, Crandall CJ, Huisman M, Khosla S, Kwok T, Mellström D, Orwoll ES, van Schoor NM,[...]

Ethical Challenges of Extracorporeal Membrane Oxygenation: Enhanced Recovery After Surgery Cardiac Society Consensus on Key Issues and Practical Recommendations

Griffee MJ, Kirsch RE, Rubin J, Peeler A, Hayanga JW, Chatterjee S, Dorsey D, Emeruwa IO, Goodwin ML, Rubin EB, Kim BS, Grant MC, Zaaqoq[...]

Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron D, Nallamshetty S, Din N, Zitko K, Khachatourian K, Skaar JR, Tonnu-Mihara I. Systemic Inflammation and[...]